1	Kinetics of viral load, immunological mediators and characterization of a SARS-CoV-2					
2	isolate in mild COVID-19 patients during acute phase of infection					
3	Running Title: Virus and inflammation in mild COVID-19 cases					
4	Anbalagan Anantharaj <sup>1*</sup> , Sunil Gujjar <sup>1*</sup> , Saurabh Kumar <sup>1*</sup> , Nikhil Jain <sup>2</sup> , Jigme Wangchuk <sup>1</sup> ,					
5	Naseem Ahmed Khan <sup>1</sup> , Aleksha Panwar <sup>1</sup> , Akshay Kanakan <sup>3</sup> , Vivekanand A <sup>3,4</sup> , Janani Srinivasa					
6	Vasudevan <sup>3</sup> , Asim Das <sup>2</sup> , Anil Kumar Pandey <sup>2</sup> , Rajesh Pandey <sup>3</sup> and Guruprasad R. Medigeshi <sup>1</sup>					
7						
8	1: Clinical and Cellular Virology lab and Bioassay Laboratory, Translational Health Science and					
9	Technology Institute, Faridabad, Haryana. INDIA.					
10	2: Employees State Insurance Corporation Medical College and Hospital, Faridabad, Haryana,					
11	INDIA.					
12	3: CSIR-Institute of Genomics and Integrative Biology, Delhi, INDIA.					
13	4: Academy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, INDIA.					
14	* These authors contributed equally					
15						
16	# Corresponding author:					
17	Guruprasad R. Medigeshi, PhD					
18	Translational Health Science and Technology Institute,					
19	NCR-Biotech Science Cluster,					
20	P.O. Box # 4, Faridabad-Gurgaon Highway,					
21	Faridabad 121001. INDIA.					
22	Tel: +91-0129-2876311.					
23	Email: gmedigeshi@thsti.res.in					

#### 24 ABSTRACT

Over 95% of the COVID-19 cases are mild-to-asymptomatic who contribute to disease 25 transmission whereas most of the severe manifestations of the disease are observed in elderly and 26 27 in patients with comorbidities and dysregulation of immune response has been implicated in severe clinical outcomes. However, it is unclear whether asymptomatic or mild infections are 28 29 due to low viral load or lack of inflammation. We have measured the kinetics of SARS-CoV-2 viral load in the respiratory samples and serum markers of inflammation in hospitalized COVID-30 19 patients with mild symptoms. We observed a bi-phasic pattern of virus load which was 31 eventually cleared in most patients at the time of discharge. Viral load in saliva samples from a 32 subset of patients showed good correlation with nasopharyngeal samples. Serum interferon levels 33 were downregulated during early stages of infection but peaked at later stages correlating with 34 35 elevated levels of T-cell cytokines and other inflammatory mediators such as IL-6 and TNF-  $\alpha$ which showed a bi-phasic pattern. The clinical recovery of patients correlated with decrease in 36 viral load and increase in interferons and other cytokines which indicates an effective innate and 37 adaptive immune function in mild infections. We further characterized one of the SARS-CoV-2 38 39 isolate by plaque purification and show that infection of lung epithelial cells (Calu-3) with this isolate led to cytopathic effect disrupting epithelial barrier function and tight junctions. Finally 40 we showed that zinc was capable of inhibiting SARS-CoV-2 infection in this model suggesting a 41 beneficial effect of zinc supplementation in COVID-19 infection. 42

43

#### 44 **IMPORTANCE**

A majority of COVID-19 patients are asymptomatic or exhibit mild symptoms despite high viral
loads suggesting a key role for the acute phase innate immune response in limiting the damage

and clearing the virus. Therefore, it is important to understand the early phase response to SARS-47 CoV-2 infection in such patients to devise strategies for clinical management of the disease. Our 48 study shows the kinetics of immune mediators in the serum samples collected from hospitalized 49 COVID-19 patients with mild symptoms. We further characterize a virus isolate from one of 50 these patients and demonstrate its effect on epithelial barrier functions and show that zinc was 51 52 capable of inhibiting SARS-CoV-2 infection under these conditions. Our results suggest a key role for the innate immune responses in the early phase of infection in mitigating clinical 53 symptoms, clearing the virus and recovery from illness and suggest an antiviral role for zinc in 54 55 COVID-19 infection.

56

57 Keywords: SARS-CoV-2; COVID-19; Cytokines; Chemokines; Inflammation; Zinc; epithelial
58 cells.

#### 60 INTRODUCTION

Coronavirus disease of 2019 (COVID-19) has infected over 35 million people worldwide leading 61 to over a million deaths (as on 10th October 2020). Severe acute respiratory syndrome 62 coronavirus-2 (SARS-CoV-2), a positive-sense RNA virus from the family *Coronaviridae* is the 63 causative agent of COVID-19. The RNA genome of SARS-CoV-2 ranges from 26 to 32 64 65 kilobases in length and similar to other coronaviruses that have jumped species to infect humans, SARS-CoV-2 is believed to have been in circulation in animals such as bats for several decades 66 before infecting humans (1). The genome of SARS-CoV-2 shares about 96% identity with that of 67 bat coronavirus and is about 80% identical to the SARS-CoV-1 (2). Angiotensin converting 68 enzyme-2 (ACE2) has been reported as a primary entry receptor for SARS-CoV-2 (3). ACE2, a 69 type I membrane protein, is expressed in lungs, kidneys, intestine and heart. The spike 70 glycoprotein (S-protein) on the SARS-CoV-2 virion surface mediates the receptor recognition 71 and membrane fusion thus facilitating the entry of virus in the cell (4). There are close to 200 72 73 vaccines under development for COVID-19 and some of the vaccines have advanced to Phase III trials (5). Efforts to repurpose drugs and to manage the cytokine storm have identified a number 74 75 of drugs that have been recommended for use in COVID-19 (6) but an effective antiviral specific 76 to SARS-CoV-2 is yet to be licensed for human use.

77

Most of the patients with COVID-19 exhibit mild or no symptoms and severe clinical symptoms
are observed in patients in the older age group (>65 years) or patients with underlying
comorbidities such as hypertension and diabetes. Impaired immune response and cytokine storm
has been implicated in clinical manifestations observed in severe disease (7-9). Increased viral
load has been shown to correlate with disease severity (7, 10) and some of the antivirals such as

Remdesivir which inhibit the viral RNA-dependent-RNA-polymerase of SARS-CoV-1, Middle 83 East Respiratory Syndrome Coronavirus (MERS-CoV) and SARS-CoV-2 has been shown to 84 85 reduce time to recovery and mortality in COVID-19 patients (11). As is the case with RNA viruses, coronaviruses accumulate mutations and evolve at a rate similar to other RNA viruses 86 (12, 13). Variations in the viral genome and emergence of novel clades has been implicated in 87 increased fitness and transmission (14) however there is no evidence to suggest increased 88 virulence of infecting virus as a cause of severe disease in COVID-19 patients suggesting that 89 the host response and underlying comorbidities plays a key role in clinical outcomes (15). In this 90 study, we monitored the kinetics of viral load in respiratory samples and saliva and cytokines and 91 chemokines in the serum of hospitalized COVID-19 patients who displayed mild/moderate 92 symptoms and recovered from illness. We isolated SARS-CoV-2 from one of the patients and 93 further characterized the isolate by plaque-purification and sequencing and assessed the effect of 94 virus infection on epithelial barrier functions. Our results suggest a clear inverse correlation 95 96 between interferon response and viral load and identifies signatures in the inflammatory mediators in the serum of young patients who recover from COVID-19. We also show that the 97 98 virus isolate from a patient with mild infection is capable of infecting lung epithelial cells and 99 disrupting epithelial barrier functions leading to cell death further underscoring the importance of a robust host response in mitigating the clinical outcomes in COVID-19 infection. Finally, 100 101 addition of zinc post-infection inhibited SARS-CoV-2 infection indicating the antiviral function 102 of zinc in SARS-CoV-2 life-cycle.

103

104 MATERIALS AND METHODS

**106 Human Ethics** 

The study was approved by the Institutional ethics committees for human research at both the
institutions (No. 134/A/11/16/Academics/MC/2016/134 and THS 1.8.1/ (93)). Informed consent
was obtained from all the participants.

110

# 111 Clinical samples

112 Patients with symptoms of COVID-19 infection were diagnosed using RealStar® SARS-CoV-2

113 RT-PCR kit (altona Diagnostics GmbH) at ESIC Medical College & Hospital. Clinical

114 presentations were mild or asymptomatic (identified by contact tracing) and included mild to

moderate fever, dry cough, and loss of sense of smell and taste. As per the regulations at the time

of the study, all patients with a positive RT-PCR test were admitted to the hospital within 24-48

117 hours of testing positive and treated with azithromycin with hydroxychloroqine, Vitamin C and

118 D. Samples were collected from patients who consented to participate in the study by signing the

119 informed consent form. Nasopharyngeal/oropharyngeal (NP/OP) swab in virus transport medium

120 (VTM), saliva and serum was collected from Day 1 of enrolment till discharge. Saliva was

121 collected in specimen collection cups early in the morning immediately after the patient woke up

122 from sleep. All the samples collected daily at same interval. All patients were isolated in the

hospital for at least 14 days.

124

# 125 Virus culture and isolation

126 SARS-CoV-2 Isolate USA-WA1/2020 was obtained from BEI resources (deposited by the

127 Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH:

128 SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281). Indian isolates of SARS-

CoV-2 was isolated from COVID-19-positive VTM samples (VTM) using Vero E6 cells 129 (Obtained from National Centre for Cell Science, Pune, INDIA). 2x10<sup>6</sup> cells were grown in a 130 T25 flask to about 80% confluency. Culture medium was removed and washed once with 5 ml of 131 phosphate-buffered saline (PBS). 500 µl of VTM was added onto the cells and the flask was 132 133 incubated for 1 h at 37°C in a CO<sub>2</sub> incubator with intermittent mixing. After 1h of adsorption, 134 monolayer was washed twice with 1X PBS and DMEM supplemented with 2% fetal bovine serum (FBS) and 2X antibiotics (200 units of penicillin, 200 µg of streptomycin) and 250 ng/ml 135 amphotericin B and non-essential amino acids. Cell monolayer was observed under the 136 microscope every day. Cytopathic effect was observed usually by day two of infection when the 137 Ct value of the sample was less than 20 in RT-PCR. Culture supernatant was harvested and 138 clarified at 1000 x g and multiple small aliquots were prepared and stored at -80°C. Virus titer in 139 the supernatants were estimated by plaque assays on Vero E6 cells as per the previous protocols 140 141 (16) except that the cells were fixed at 60 h pi. Clinical specimens and virus cultures were handled in biosafety level 3 (BSL3) facility as per the standard operating procedure and 142 143 guidelines for BSL3 level pathogen.

144

#### 145 **Quantitative RT PCR**

146 RNA was extracted from 150 µl of VTM using Viral RNA Isolation Kit (MACHEREY-

147 NAGEL), and eluted in 50 µl of nuclease-free water and used as a template for quantitation of

148 SARS-CoV-2 viral RNA levels by reverse transcription polymerase chain reaction (RT-PCR).

- 149 2019-nCoV CDC Probe and Primer kit for SARS-CoV-2 manufactured (Biosearch
- 150 Technologies) was used to detect N gene by real time RT PCR. RNAse P was detected as
- endogenous control for normalization. The region of N gene starting from 28287 29230 was

amplified using the forward primer 5'-GACCCCAAAATCAGCGAAAT-3' and the reverse 152 primer 5'-GCGCGACATTCCGAAGAA-3' and cloned into pGEM®-T-Easy vector (Promega). 153 154 This clone was linearized using Sac II enzyme and in vitro transcribed using the SP6 RNA polymerase (Promega). The transcript was purified and used as a template for generating 155 standard curve to estimate the copy number. 156 For virus isolates, RNA was isolated from 4 different plaque-purified isolates using 157 QIAamp Viral RNA mini kit (Qiagen) according to manufactures instruction. SARS-CoV-2 viral 158 159 RNA was detected using RealStar® SARS-CoV-2 RT-PCR kit (altona Diagnostics GmbH). To check the presence of other respiratory virus in samples, FTlyo respiratory pathogen 21 plus kit 160 was used (Fast Track Diagnostics). This detects presence of 21 respiratory viruses which 161 includes influenza A virus; influenza A(H1N1) virus (swine-lineage); influenza B virus; human rhinovirus; 162 human coronaviruses NL63, 229E, OC43 and HKU1; human parainfluenza viruses 1, 2, 3 and 4; human 163 164 metapneumoviruses A/B; human bocavirus; human respiratory syncytial viruses A/B; human adenovirus; enterovirus; human parechovirus; Mycoplasma pneumoniae and 4 bacterial species S. aureus; C. 165 166 pneumoniae; H. influenzae B; S. pneumonia.

167

168 Multiplex cytokine/chemokine assays

169 25 µl of serum was used for in magnetic bead-based multiplex chemokine and cytokine luminex 170 assay as per the manufacturer's instructions (Merck-Millipore). Assays were performed in 171 duplicates along with quality controls. The amount of each analyte was estimated by standard 172 curve generated using known amount of analyte provided in the assay kit. Assay plates were read 173 using MAGPIX system and data was analysed by xPONENT software using five parametric 174 logistic fit model. 175

176	Cell Viability assay
177	Cell viability assay was performed using CellTiter-Glo® Assay kit (Promega) according to user
178	manual. Briefly, 20,000 Calu-3 cells were seeded in 96 well plate and grown for 48 h. Cells were
179	treated with zinc sulfate at indicated concentrations. After 24 h post treatment CellTiter-Glo
180	reagent was added to the well and luminescence was measured by microplate reader (Synergy
181	HT - BioTek).
182	
183	Labile zinc level measurement
184	Labile Zn levels in the cells were estimated as described before (17). Briefly, after incubation
185	with zinc sulfate, cells were washed once with PBS, detached using trypsin and resuspended in
186	staining medium (DMEM without phenol red supplemented and with 2 mM L-glutamine; Gibco)
187	containing 2.5 µM ZinPyr-1 (ZP-1) (Santa Cruz) for 30 min at 37°C. Cells were washed using
188	fluorescence-activated cell sorter (FACS) buffer (PBS containing 0.25% FBS), and samples were
189	acquired in a FACS Canto II apparatus (Becton, Dickinson). The amounts of labile zinc present
190	in the cells are presented as the mean fluorescence intensities of ZP-1.
191	
192	Immunofluoresence
193	VeroE6, Calu-3 (ATCC) and Caco-2 (ATCC) cells were seeded at 50,000 cells per well in 48-
194	well plate. Calu-3 and Caco-2 cells were seeded 2 days prior whereas VeroE6 were seeded a day

before infection. Cells were infected with SARS-CoV-2 THSTI-BL2010-D at 0.3, 1 and 3 MOI.

196 After 1 h of adsorption, viral inoculum was removed. Cells were washed twice with PBS. Cells

197 were kept in complete medium (10% FBS containing DMEM with penicillin, streptomycin and

glutamine mix and non-essential amino acids). At 24 h pi, cells were washed twice with PBS and 198 once with cold PBS and fixed by using ice cold methanol and kept at -20°C for 20 min. Methanol 199 200 was removed, cells were washed once with cold PBS and then once with PBS at room temperature (RT), followed by blocking with 0.2% BSA-PBS for 10 min at RT. Cells were 201 incubated with human chimeric SARS-CoV-2 S1 spike antibody (1: 100 dilution; Genescript -202 203 HC2001) in 0.2% BSA-PBS for 1h at RT. Cells were then washed three times with 0.2% BSA-PBS. This was followed by incubation with secondary antibody conjugated with anti-human 204 Alexa flour 488 (1:500; Life Technologies–A11013) for 30 min at room temperature in dark. 205 Cells were washed with PBS three times and stained with 4',6-diamidino-2-phenylindole (DAPI) 206 (Molecular probes) at 1:10,000 dilution for 10 min. Cells were washed with PBS and images 207 were captured using Olympus DP80 microscope at 20X magnification. Images were processed 208 209 by background subtraction using cellSens software. Bright field images were captured using Nikon Eclipse Ti-S at 10X magnification. 210

211

#### 212 **Zinc treatment**

Calu-3 cells (40-50K) were seeded in a 24-well plate and two days post-infection, cells were
infected with 0.3 MOI of SARS-CoV-2. Cells were cultured in serum-free MEM containing
indicated concentrations of zinc sulfate for 24 hours. Viral titers in the supernatant was measured
by plaque assays as described above.

217

#### 218 Whole genome Sequencing and analysis

219 The protocol followed for the sample preparation, sequencing, and data analysis has been

described earlier (18). In brief, double-stranded cDNA was synthesized from 50ng of total RNA

221	from virus stocks for all the four plaque-purified SARS-CoV-2 isolates. The first strand of
222	cDNA was synthesized using Superscript IV followed by RNA digestion with RNase H for
223	second-strand synthesis using DNA Polymerase I Large fragment (Klenow fragment). 100ng of
224	purified double-stranded cDNA was taken for forward using ARTIC tiling PCRprotocol (V3
225	primer pools) (https://artic.network/ncov-2019) (19). 200ng of each purified sample of
226	multiplexed PCR amplicons obtained was taken for library preparation using Oxford Nanopore
227	Technology (ONT). This included End Repair/dA tailing, Native Barcode Ligation, and Adapter
228	Ligation of the PCR amplicons. 100ng of the pooled and purified library was sequenced using
229	ONT's MinION Mk1B platform (18).
230	Samples were base-called and demultiplexed using Guppy basecaller (version
231	3.5.2)( <u>https://community.nanoporetech.com</u> ). Reads having phred quality score < 7 were
232	discarded to filter the low-quality reads. The resulting fastq files were normalized by read length
233	(300-500) and reads were aligned using Minimap2 (v2.17) (20) to the reference (GenBank:
234	MN908947.3). Variants were called using Nanopolish(21) from the aligned reads and further
235	creating consensus fasta using bcftools (v1.8). Finally, we used Nextclade
236	(https://clades.nextstrain.org/) for the detection of clades from the consensus fastasequence.All
237	the sequences are submitted to the GISAID database ( <u>https://www.gisaid.org/</u> ; GISAID EPI ISL
238	- 454862).

239

# 240 Phylogenetic analysis

The consensus genomes obtained from the whole genome sequencing of 10 Indian isolates and
four plaque-purified Indian isolates along with 86 other global SARS-CoV-2 sequences were
used for constructing the phylogeny. The sequences were selected from a diverse geographical

location to represent the global distribution and spread of the virus. The sequences were obtained
from the Global Initiative on Sharing All Influenza Data (GISAID) database. The fasta
sequences were aligned using MUSCLE (22). A maximum-likehood Phylogeny was generated
using FastTree 2.1.11 (23)with generalized time-reversible (GTR) substitution model and 1000
bootstrap replicates with default parameters. The tree was visualized and edited using ITOL (24).

# 250 Trans-epithelial electrical resistance and confocal microscopy

Calu-3 cells were grown in air-liquid interface as described elsewhere (25). Briefly, Calu-3 cells 251 were seeded at 30,000 on 3 µm pore size transwell inserts (Corning - 3415). Cells were 252 maintained at liquid-liquid interface for 7 days and cells were further grown with 600 µl of 253 complete medium only in the basolateral compartment. Media was replaced every alternate day. 254 255 TEER was monitored at indicated time points using a chop stick electrode (Millipore). On day 21 post-seeding, cells were infected with SARS-CoV-2-THSTI-BL2010D as described. At 24 h 256 257 pi, culture inserts were washed with cold 1X PBS and incubated with cold methanol at -20°C for 20 minutes. Cells were further incubated with IMF buffer (20 mM HEPES, pH 7.5, 0.1% Triton-258 259 X-100, 150 mM sodium chloride, 5 mM EDTA and 0.02% sodium azide as a preservative) for 5 260 min at room temperature (RT) and all further washes were performed with IMF buffer. Nonspecific antibody binding sites were blocked by incubating cells with IMF buffer containing 2% 261 262 normal goat serum for 10 min at RT. Membranes were cut out using a scalpel blade and 263 transferred to a 48-well plate. Cells were washed three times followed by incubation with 264 antibodies against ZO-1 (Becton Dickinson), Claudin-3 (Invitrogen), SARS-CoV-2 spike antibody in IMF buffer (20 mM HEPES pH 7.5, 0.1% Triton X-100, 150 mM NaCl, 5 mM 265 EDTA, 0.02 % sodium azide) for 1 h at RT. Cells were washed followed by incubation with 266

appropriate secondary antibodies tagged with Alexa fluor 488/568/633 (Molecular probes) for 30
min at RT by avoiding exposure to light. Cells were washed with IMF buffer three times and
stained with DAPI at 1:10,000 dilution for 10 min. Cells were washed with PBS, mounted on
glass slide using antifade solution (Molecular probes) and images were captured at 100X
magnification using FV3000 confocal microscope (Olympus). Images were processed by
background subtraction using cellSens software (Olympus).

273

# 274 Data analysis

275 Data was analysed and final graphs were prepared using GraphPad Prism (Version 7.0e)

software. All experiments were performed with two or more replicates and graphs have been

prepared representing data from at least two independent experiments with  $n \ge 6$  unless

otherwise indicated. Statistical significance was estimated by t-test (unpaired, non-parametric)

279 using Mann-Whitney method.

280

# 281 **RESULTS**

# 282 Kinetics of viral load in COVID-19 patients with mild symptoms

11 patients who were positive for COVID-19 by RT-PCR were enrolled for the study after

obtained informed consent. The median age of the patients was 32 (25% Percentile 24, 75%

Percentile 45) and the mean duration of hospitalization was 14 days (Std. Dev. 4.034 days). Out

of the 11 patients 6 were male and 5 were female. NP & OP swabs, saliva and serum samples

collected for a maximum of 10 days. Most of the patients in this study manifested mild

symptoms and were asymptomatic at the time of discharge. We measured daily viral load in the

289 NP/OP samples by RT-PCR. For a subset of patients (n=5), we collected saliva samples early in

the morning for estimation of viral load in saliva and compare with the NP/OP sample. Viral 290 load in NP/OP swab samples peaked between day 2 to 4 in most patients and we observed a 291 292 biphasic increase in viral RNA levels in few patients with a second peak on day 5 (Figure 1A-1F). The peak viral RNA levels ranged from  $10^6$  to  $10^{10}$  copies per ml of virus transport medium. 293 Except for one patient, viral load in saliva correlated with viral load in VTM samples (Figure 294 295 1H-1K). In one patient, virus persisted in saliva till day 10 while the VTM sample was RT-PCR negative by day 6 of enrolment (Figure 1G). In most cases, the viral RNA was below the level 296 of detection by RT-PCR by day 7-9 but two patients showed increasing trend in viral RNA levels 297 although the last sample in these patients were on day 5 and day 7 (Figure 1D and 1H). These 298 data suggest that the mild or asymptomatic patients harbour high viral load and salivary viral 299 300 load can be a good alternate for the NP/OP swabs.

301

#### 302 Kinetics of inflammatory mediators in mild/asymptomatic COVID-19 patients

303 As recent reports implicate both virus and host factors in severe COVID-19 disease, we were interested in estimating the levels of some of the inflammatory mediators along with interferons 304 305 in the serum samples collected daily from mild COVID-19 patients to understand the correlates 306 of recovery from disease. We measured 15 serum inflammatory mediators in each of the samples by multiplexing using luminex technology. The analytes detected are namely IFN- $\alpha$ 2, IFN- $\gamma$ , IL-307 1B, IL-4, IL6, IL-7, IL-8, IL10, IL12p40, IL12p70, IL17A, Monocyte Chemotactic Protein 308 309 1(MCP-1), MCP-3, TNF- $\alpha$  and gamma interferon inducible protein -10 (IP-10). We observed a consistent decrease in type I and type II during the acute phase of infection but both IFN- $\alpha$ 2 and 310 311 IFN- $\gamma$  increased at later stages of infection coinciding with recovery and clearance of virus by day 8 of enrolment (Figure 2A). We next looked at the cytokines that influence T-cell functions 312

namely the pro-inflammatory IL-12p40 homodimer or IL-12p70, the active IL-12 heterodimer 313 314 secreted by dendritic cells and macrophages that promotes Th1 response and leads to IFN- $\gamma$  and 315 TNF- $\alpha$  production. We observed a clear increase in IL-12p70 levels from day 5 onwards suggesting priming of T cells by the innate immune system through IL-12p70 secretion (Figure 316 2B). This increase coincided with increased IFN- $\gamma$  levels observed in the same samples (Figure 317 318 1A). IL-7, a cytokine produced by epithelial cells and DCs and promotes biogenesis and proliferation of lymphocytes also showed an increasing trend coinciding with IL-12p70. 319 However IL-17A levels did not show a significant change suggesting a more prominent role for 320 321 Th1 responses in recovery in mild COVID-19 cases. Contrasting with the IFN responses, the levels of IL-8 was elevated at early stages of infection suggesting a key role for innate immune 322 cells such as macrophages which produce IL-8 thus promoting neutrophil recruitment to the site 323 of infection leading to resolution of infection. Interestingly, the levels of other two pro-324 inflammatory chemokines IP-10 and MCP-1 did not show any variation and MCP-3 levels were 325 very heterogenous during the course of infection in any of the patients suggesting lack of severe 326 inflammatory response in these patients (Figure 2C). IL-6, an acute phase reactant which is 327 implicated in the severe manifestations of severe COVID-19 symptoms showed a moderate 328 329 increase in multiple phases but TNF- $\alpha$  levels were unchanged in majority of the patients. The levels of IL-10, IL-4 and IL-1β showed an increasing trend in samples from day 5 - day 8 of 330 infection suggesting the activation of T cells (Figure 2D). Overall our data suggests a prominent 331 role for the innate immune response in clearance of virus infection/infected cells at early states of 332 333 infection and priming of adaptive immune responses which probably lead to long-term protection from re-infection. 334

#### 336 Isolation and characterization of SARS-CoV-2

Increased viral loads have been associated with severe disease by previous reports (7, 15). We 337 338 were interested in understanding whether the virus isolates from mild or asymptomatic infection have altered ability to evade immune response and cause cellular damage. In order to isolate and 339 characterize an Indian isolate of SARS-CoV-2, we used NP/OP swab samples from six COVID-340 341 19 patients whose samples had a Ct value of 20 or less by the diagnostic RT-PCR. Vero E6 cells were inoculated with NP/OP swab samples and culture supernatant was harvested on day 2 post-342 infection when cytopathic effect was evident to generate passage 1 virus. The process was 343 repeated two more times to generate passage 2 and passage 3 viruses (Supplementary Figure S1). 344 One of the passage 3 isolate, THSTI-BL2010-D, was further plaque-purified by isolating four 345 individual plaques (THSTI-BL2010-A through D) and propagating further one more time in 346 Vero E6 cells to generate a large stock of passage 5 virus for all experiments (Figure 3A). All the 347 plaque-purified virus showed CPE at 72 h pi. All the plaque-purified viruses were negative for 348 349 21 respiratory viruses and 4 bacterial species including Mycoplasma as assessed by RT-PCR indicating lack of any secondary pathogens. Next, we performed plaque assays to compare the 350 351 plaque morphology of plaque-purified virus on VeroE6 cell-monolayer with SARS-CoV-2 USA-352 WA1/2020 isolate. Both the isolates developed plaques at 60 h pi, however, the plaque-purified isolate produced a more homogenous plaque size and distribution as compared to the USA-353 354 WA1/2020 isolate (Figure 3B).

355

#### 356 SARS-CoV-2 infection in human epithelial cell lines

357 Infection of SARS-CoV-2 in human cell lines depends on the expression of its receptor

angiotensin-converting enzyme 2 (ACE2) and the host protease TMPRSS2 (26). To confirm the

infectivity of THSTI-BL2010-D in human cell lines, we infected Vero E6, Calu-3 and Caco-2 359 cells with increasing MOIs of the virus and stained for the presence of spike protein by 360 361 immunofluorescence assay at 24 h pi. As expected, Vero E6 cells showed the maximum infection followed by Calu-3 cells and Caco-2 cells (Figure 4A). We next compared growth 362 curve of SARS-CoV-2 Wuhan strain and THSTI-BL2010D in Vero E6 cells. Cells were infected 363 with 0.1 MOI of both strains and supernatants were collected at 24, 48 and 72 h pi. Plaque assay 364 results showed titres of Wuhan strain was a log higher than THSTI-BL2010D at 24 h pi whereas 365 at 48 h pi virus titres with both strains were similar (Figure 4B). Virus titers showed a declining 366 trend at 72 h pi most probably due to cytopathic effect. 367

368

#### 369 Whole genome sequencing

To further characterize the plaque-purified isolates at molecular level, we isolated RNA from the 370 plaque-purified virus stocks and subjected to whole genome sequencing. All the four plaque-371 372 purified virus RNA samples showed similar changes in the nucleotide positions with most changes in the ORF1a region leading to five non-synonymous and one synonymous change in 373 374 the protein sequence (Table 1). THSTI-BL-2010-C sample had one additional mutation 375 G27806T resulting in a synonymous change in ORF7b. Two non-synonymous changes were also 376 observed in ORF1b and N regions (Table 1). Interestingly, none of the Indian isolates in our 377 study showed D614G mutations observed elsewhere which is associated with increased 378 infectivity (27). The slippery heptanucleotide sequence and the pseudoknot structure were not 379 disrupted in any of the samples as per the sequence alignment compared to the reference genome (Accession ID: MN908947.3). The phylogenetic analysis of the 100 representative SARS-CoV-2 380 sequences from around the world (Supplementary Table S1) revealed clustering of sequences 381

into five major clades according to the GISAID nomenclature system (https://www.gisaid.org).
Sequences from all the 14 genomes from our study were subjected to phylogenetic analysis and
were assigned to clade 19A which along with the 19B clade forms the earliest clade which
originated from Wuhan and was prevalent in Asia during the initial months of the outbreak
(Figure 5). This suggests that the SARS-CoV-2 isolates reported in our study are genetically
more similar to the reference Wuhan sequence (GenBank: MN908947.3).

388

# 389 SARS-CoV-2 infection disrupts epithelial barrier

We were further interested to investigate the effect of THSTI-BL-2010D isolate infection on 390 epithelial barrier functions. Polarized Calu-3 cells grown on transwells were infected with 391 SARS-CoV-2 at 0.3 MOI. TEER was measured at 24 h pi and virus titers in the apical and 392 basolateral supernatants were estimated by plaque assays. We observed a 60% reduction in 393 TEER values as compared to mock at 24 h pi indicating disruption of epithelial barriers as a 394 395 result of cytopathic effect (Figure 6A). As expected, virus was present both in the apical and basolateral samples due to disruption of cellular junctions and polarity (Figure 6B). Cells were 396 397 stained for virus spike protein, ZO-1 and claudin-3 antibodies to visualize infected cells and 398 staining pattern of these representative junctional proteins. We observed disruption of both ZO-1 and claudin-3 staining in virus-infected cells but not in mock-infected cells (Figure 6C) 399 400 suggesting that SARS-CoV-2 isolated from an mild/asymptomatic patient infects polarized lung 401 epithelial cells and causes damage to epithelial barriers due to cytopathic effect.

402

# 403 Zinc supplementation affects SARS-CoV-2 infection *in vitro*

Addition of zinc along with the zinc ionophore pyrithione, which stimulates zinc uptake, was 404 shown to inhibit SARS-CoV infection in Vero E6 cells (28). We were interested to use our cell 405 406 culture system to assess whether zinc has an inhibitory effect on SARS-CoV-2 infection. We first determined cytotoxicity and uptake of zinc in Calu-3 cells by treating cells with different 407 concentration of ZnSO<sub>4</sub> at 25, 50 and 100  $\mu$ M for 24 h. We observed cytotoxicity beyond 50  $\mu$ M 408 409 ZnSO<sub>4</sub> in Calu-3 cells (Figure 6D). Zinc uptake was determined by staining cells with zinc fluorophore, ZP-1, at 4 h post-treatment. Cells treated with 25 µM of ZnSO<sub>4</sub> showed 25% 410 increase in labile zinc levels whereas cells treated with 50 µM of ZnSO<sub>4</sub> shows 50% increase in 411 labile zinc levels as compared to mock-treated control suggesting that these cells are capable of 412 zinc uptake (Supplementary Figure S2). Cells were infected with SARS-CoV-2 at 0.3 MOI and 413 cultured in the presence of 25 and 50 µM of ZnSO<sub>4</sub> for 24 h. At 24 h pi viral titres in the 414 supernatant was determined by plaque assay. Zinc treatment showed over three-fold reduction in 415 viral titers at 24 h pi as compared to untreated cells (Figure 6E) indicating the antiviral effect of 416 417 zinc salts on SARS-CoV-2 infection in these cells.

418

#### 419 **Discussion**

Of all the coronavirus epidemic/pandemic of recent past, COVID-19 has had the maximum impact on global health and economy. Although most of the individuals are asymptomatic or with mild symptoms, the disease affects the elderly and people with co-morbidities the most indicating a critical role for innate immune response in limiting the viral load and spread. Most asymptomatic or individuals with mild symptoms harbour high viral loads in their respiratory tract and contribute to disease transmission. Previous report suggested reduced interferon response in severe patients as compared to mild/moderate cases 8-12 days after the onset of

symptoms (7) and viral genetics was not found to correlate with severe disease (15). We 427 focussed our efforts to monitor the kinetics of viral load and inflammatory mediators in the 428 429 serum samples of hospitalized COVID-19 patients who displayed mild to no symptoms but were RT-PCR positive for SARS-CoV-2 during screening at the hospital or contact tracing. Most of 430 our patients were enrolled within 48 hours of testing positive and are likely to be within the first 431 432 week of exposure to the virus. In patients where we could detect viral RNA in saliva samples, the viral load in saliva correlated well with the same in VTM samples suggesting that saliva sample 433 could replace NP/OP swabs which cause discomfort to patients during sample collection. 434 Collection of saliva would also reduce the cost and time involved in sample collection for 435 COVID-19 diagnosis and self-sampling by patients would reduce the risk of exposure for health 436 care workers. The copy numbers of viral RNA, as estimated by quantifying the nucleocapsid 437 gene region, varied by four orders magnitude suggesting multiple factors including the initial 438 inoculum as a major determinants of viral load in the respiratory tract. Despite this huge 439 440 variation in viral load, the clinical features and disease outcome did not vary as all patients were able to clear the virus and recover from the disease. This clearly suggests that a robust immune 441 442 response in younger adults is capable to clearing the infection and age and imbalance in immune 443 response could contribute to severe disease in older individuals and patients with co-morbidities. We observed that decrease in viral loads coincided with increase in IFN responses which is in 444 445 agreement with observations made by other groups in *ex vivo*, cell culture and animal models where SARS-CoV-2 was shown to be a more potent inhibitor of IFN responses than SARS-CoV-446 447 1 (29, 30). Although our study does not have relative comparison between samples from different severities, we observed a consistent decrease in type I and type II during the acute 448 phase of infection. Low serum interferons preceded respiratory failure in critical COVID-19 449

cases (7) whereas we observed an increase in both IFN- $\alpha$  and IFN- $\gamma$  in all the patients who 450 451 recovered and were discharged in our study clearly indicating a critical role for interferon 452 responses in recovery from COVID-19. Increase in type I and II interferons indicate activation of T cells and NK cells in addition to the monocytes and macrophages which may contribute to the 453 interferon levels. We have not assessed the levels of IFN- $\lambda$  in these samples which is known to 454 play a major role in antiviral response from epithelial cells (31). Our results show that there was 455 moderate to no induction of pro-inflammatory cytokines or chemokines such as IL-6, TNF- $\alpha$ , IP-456 10 in any of these patients. We also observed, at later stages of infection, a trend showing 457 458 increase in IL-10, IL-4 and IL-1B and IL-12p70 suggesting activation of T cells. Interestingly, IL-8, the primary chemoattractant for neutrophil recruitment has been shown to play an 459 important role in acute respiratory distress syndrome (ARDS) and in recruitment of neutrophils 460 to the site of injury in lungs in sepsis (32). We speculate that generation of high levels of IL-8 by 461 the cells of innate immune system such as macrophages leading to activation of neutrophils 462 which engage in viral clearance from the respiratory tract. Interestingly, neutrophils have been 463 shown to play a crucial antiviral role in influenza A virus infection and in neurotropic 464 coronavirus models such as mouse hepatitis virus (33). However, sustained levels of IL-8 may 465 466 lead to ARDS observed in severe COVID-19 patients. Therefore, we hypothesize that regulation of IL-8 signalling and neutrophil activity could be an important determinant of clinical outcomes 467 in COVID-19 patients. 468

469

An earlier study from India reported the isolation of SARS-CoV-2 from an Indian patient and its
characterization (34). We got one step further and generate the first plaque-purified SARS-CoV2 isolate from India. Plaque-purified SARS-CoV-2 revealed clear and homogeneous plaques on

Vero E6 monolayers compared to the Wuhan strain where the plaques were very heterogeneous 473 in size. As robust and consistent plaque reduction neutralization titers (PRNT) depend on high 474 475 quality plaque assays, we believe our virus strain will help in establishing PRNT assays that could work reliably and consistently and help vaccine studies. Although SARS-CoV-2 primarily 476 targets the respiratory system, *in vitro* and *in vivo* studies indicate broad tissue tropism (35). In 477 478 contrast to a previous study which showed no difference between the permissibility of Calu-3 and Caco-2 cells for SARS-CoV-2 infection (35), the Indian SARS-CoV-2 isolate from our study 479 infected Calu-3 cells better than Caco-2 cells. Interestingly, cell surface expressions of ACE2 on 480 Caco-2 cells was shown to be higher than Calu-3 cells grown on trans-well inserts (36). 481 Therefore, it would be interesting to investigate the difference in ACE2 expression under 482 different growth conditions and passage history of cell lines to correlate with their susceptibility 483 to infection by SARS-CoV-2. Finally, based on previous reports which demonstrate the 484 inhibitory activity of zinc on coronavirus RNA polymerase (28) and the widely accepted 485 486 beneficial role of zinc supplementation in respiratory infections (37), we show presence of excess zinc was inhibitory to SARS-CoV-2 in Calu-3 cells. As zinc is an acute-phase reactant 487 488 which undergoes tissue redistribution during infection, our data suggests a beneficial effect of 489 zinc supplementation in COVID-19 infection.

490

#### 491 ACKNOWLEDGEMENTS

We thank Amresh Kumar Singh for technical support and all members of CCV lab and bioassay
lab for their technical help and critical inputs. We thank all the patients who consented to
participate in the study.

# 496 AUTHOR CONTRIBUTIONS

-57 $111, 50, 512, 577, 17112, 11112, 1112, 1112, 557 and 101 performed experiments and and$
--

498 the data. AD and AKP coordinated the study at clinical site and contributed reagents. GRM

499 conceived the study, designed the experiments, and analyzed data. AA, SG, SK, JW and GRM

500 wrote the manuscript. All authors have reviewed and approved the final version of the

501 manuscript.

502

# 503 CONFLICT OF INTEREST STATEMENT

504 The authors declare that they have no conflict of interest to disclose.

505

## 506 FUNDING INFORMATION

507 This work was supported by funding to GRM by the Biotechnology Industry Research

508 Assistance Council (BIRAC) (BT/NBM0099/02/18). GRM also received funding from the DBT-

509 Wellcome trust India Alliance intermediate fellowship (IA/S/14/1/501291). RP acknowledges

funding support from CSIR (MLP-2005), and FondationBotnar (CLP-0031). The funders had no

role in study design, data collection and interpretation or the decision to submit the work for

512 publication.

513

#### 514 **REFERENCES**

- 515 1. Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, Rambaut A, Robertson DL.
- 516 2020. Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the
- 517 COVID-19 pandemic. Nat Microbiol doi:10.1038/s41564-020-0771-4.

- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL,
   Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Liu MQ, Chen Y, Shen XR, Wang X, Zheng
   XS, Zhao K, Chen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL.
- 521 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin.
  522 Nature 579:270-273.
- 523 3. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens
- 524 TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. 2020. SARS-
- 525 CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven
  526 Protease Inhibitor. Cell 181:271-280 e8.
- Wan Y, Shang J, Graham R, Baric RS, Li F. 2020. Receptor Recognition by the Novel
   Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS
   Coronavirus. J Virol 94.
- 5. Tregoning JS, Brown ES, Cheeseman HM, Flight KE, Higham SL, Lemm NM, Pierce BF,
  Stirling DC, Wang Z, Pollock KM. 2020. Vaccines for COVID-19. Clin Exp Immunol
  doi:10.1111/cei.13517.
- 533 6. Heimfarth L, Serafini MR, Martins-Filho PR, Quintans JSS, Quintans-Junior LJ. 2020.
- 534 Drug repurposing and cytokine management in response to COVID-19: A review. Int 535 Immunopharmacol 88:106947.
- 536 7. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, Pere H, Charbit B,
- 537 Bondet V, Chenevier-Gobeaux C, Breillat P, Carlier N, Gauzit R, Morbieu C, Pene F,
- 538 Marin N, Roche N, Szwebel TA, Merkling SH, Treluyer JM, Veyer D, Mouthon L, Blanc
- 539 C, Tharaux PL, Rozenberg F, Fischer A, Duffy D, Rieux-Laucat F, Kerneis S, Terrier B.

- 540 2020. Impaired type I interferon activity and inflammatory responses in severe COVID-19
  541 patients. Science 369:718-724.
- 542 8. Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y,
  543 Cheng X, Zhu C, Xia Y. 2020. Profiling serum cytokines in COVID-19 patients reveals
- 544 IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect 9:1123-1130.
- 545 9. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H,
- 546 Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q. 2020.
- 547 Clinical and immunological features of severe and moderate coronavirus disease 2019. J
  548 Clin Invest 130:2620-2629.
- Pujadas E, Chaudhry F, McBride R, Richter F, Zhao S, Wajnberg A, Nadkarni G,
  Glicksberg BS, Houldsworth J, Cordon-Cardo C. 2020. SARS-CoV-2 viral load predicts
  COVID-19 mortality. Lancet Respir Med 8:e70.
- 552 11. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu
- 553 HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V,
- Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC,
- 555 Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fatkenheuer G, Kortepeter MG,
- 556 Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett
- T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC, Members A-SG. 2020.
  Remdesivir for the Treatment of Covid-19 Final Report. N Engl J Med doi:10.1056/NEJMoa2007764.
- 560 12. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, Boerwinkle E, Fu YX. 2004. Moderate
  561 mutation rate in the SARS coronavirus genome and its implications. BMC Evol Biol 4:21.

- Forni D, Cagliani R, Clerici M, Sironi M. 2017. Molecular Evolution of Human Coronavirus Genomes. Trends Microbiol 25:35-48.
   Koyama T, Platt D, Parida L. 2020. Variant analysis of SARS-CoV-2 genomes. Bull World Health Organ 98:495-504.
   Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S, Chen J, Wang W, Chen B, Jiang L, Yu S, Lu J, Wang J, Xu M, Yuan Z, Zhang Q, Zhang X, Zhao G, Wang
- S, Chen S, Lu H. 2020. Viral and host factors related to the clinical outcome of COVID19. Nature 583:437-440.
- Agrawal T, Schu P, Medigeshi GR. 2013. Adaptor protein complexes-1 and 3 are involved
  at distinct stages of flavivirus life-cycle. Sci Rep 3:1813.
- Kar M, Khan NA, Panwar A, Bais SS, Basak S, Goel R, Sopory S, Medigeshi GR. 2019.
  Zinc Chelation Specifically Inhibits Early Stages of Dengue Virus Replication by
  Activation of NF-kappaB and Induction of Antiviral Response in Epithelial Cells. Front
  Immunol 10:2347.
- 576 18. Kumar P, Pandey R, Sharma P, Dhar M, A. V, Uppili B, Vashisht H, Wadhwa S, Tyagi N,
- 577 Fatihi S, Sharma U, Singh P, Lall H, Datta M, Gupta P, Saini N, Tewari A, Nandi B, Kumar
- 578 D, Bag S, Gahlot D, Rathore S, Jatana N, Jaiswal V, Gogia H, Madan P, Singh S, Singh P,
- 579 Dash D, Bala M, Kabra S, Singh S, Mukerji M, Thukral L, Faruq M, Agrawal A, Rakshit
- 580 P. 2020. Integrated genomic view of SARS-CoV-2 in India [version 1; peer review: 2
  581 approved]. Wellcome Open Research 5.
- Quick J, Grubaugh ND, Pullan ST, Claro IM, Smith AD, Gangavarapu K, Oliveira G,
   Robles-Sikisaka R, Rogers TF, Beutler NA, Burton DR, Lewis-Ximenez LL, de Jesus JG,
   Giovanetti M, Hill SC, Black A, Bedford T, Carroll MW, Nunes M, Alcantara LC, Jr.,

- 585 Sabino EC, Baylis SA, Faria NR, Loose M, Simpson JT, Pybus OG, Andersen KG, Loman
- NJ. 2017. Multiplex PCR method for MinION and Illumina sequencing of Zika and other
  virus genomes directly from clinical samples. Nat Protoc 12:1261-1276.
- 588 20. Li H. 2018. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics
  589 34:3094-3100.
- Loman NJ, Quick J, Simpson JT. 2015. A complete bacterial genome assembled de novo
  using only nanopore sequencing data. Nat Methods 12:733-5.
- 592 22. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and high
  593 throughput. Nucleic Acids Res 32:1792-7.
- 594 23. Price MN, Dehal PS, Arkin AP. 2010. FastTree 2--approximately maximum-likelihood
  595 trees for large alignments. PLoS One 5:e9490.
- Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: recent updates and new
  developments. Nucleic Acids Res 47:W256-W259.
- 598 25. Braakhuis HM, He R, Vandebriel RJ, Gremmer ER, Zwart E, Vermeulen JP, Fokkens P,
- 599 Boere J, Gosens I, Cassee FR. 2020. An Air-liquid Interface Bronchial Epithelial Model
- for Realistic, Repeated Inhalation Exposure to Airborne Particles for Toxicity Testing. J
  Vis Exp doi:10.3791/61210.
- 602 26. Matsuyama S, Nao N, Shirato K, Kawase M, Saito S, Takayama I, Nagata N, Sekizuka T,
- Katoh H, Kato F, Sakata M, Tahara M, Kutsuna S, Ohmagari N, Kuroda M, Suzuki T,
  Kageyama T, Takeda M. 2020. Enhanced isolation of SARS-CoV-2 by TMPRSS2expressing cells. Proc Natl Acad Sci U S A 117:7001-7003.
- Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N,
  Giorgi EE, Bhattacharya T, Foley B, Hastie KM, Parker MD, Partridge DG, Evans CM,

608		Freeman TM, de Silva TI, Sheffield C-GG, McDanal C, Perez LG, Tang H, Moon-Walker
609		A, Whelan SP, LaBranche CC, Saphire EO, Montefiori DC. 2020. Tracking Changes in
610		SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus.
611		Cell 182:812-827 e19.
612	28.	te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. 2010.
613		Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc
614		ionophores block the replication of these viruses in cell culture. PLoS Pathog 6:e1001176.
615	29.	Chu H, Chan JF, Wang Y, Yuen TT, Chai Y, Hou Y, Shuai H, Yang D, Hu B, Huang X,
616		Zhang X, Cai JP, Zhou J, Yuan S, Kok KH, To KK, Chan IH, Zhang AJ, Sit KY, Au WK,
617		Yuen KY. 2020. Comparative Replication and Immune Activation Profiles of SARS-CoV-
618		2 and SARS-CoV in Human Lungs: An Ex Vivo Study With Implications for the
619		Pathogenesis of COVID-19. Clin Infect Dis 71:1400-1409.
620	30.	Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, Jordan TX,
621		Oishi K, Panis M, Sachs D, Wang TT, Schwartz RE, Lim JK, Albrecht RA, tenOever BR.
622		2020. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
623		Cell 181:1036-1045 e9.
624	31.	Felgenhauer U, Schoen A, Gad HH, Hartmann R, Schaubmar AR, Failing K, Drosten C,
625		Weber F. 2020. Inhibition of SARS-CoV-2 by type I and type III interferons. J Biol Chem
626		295:13958-13964.
627	32.	Groeneveld ABJ. A Central Role of Interleukin-8 in the Pathogenesis of ARDS, p 65-74.
628		In (ed), Springer Berlin Heidelberg,
620	22	Calani IE Androakog E 2015 Noutranhils in viral infactions: Current concents and

Galani IE, Andreakos E. 2015. Neutrophils in viral infections: Current concepts and
caveats. J Leukoc Biol 98:557-64.

34. Sarkale P, Patil S, Yadav PD, Nyayanit DA, Sapkal G, Baradkar S, Lakra R, Shete-Aich 631 A, Prasad S, Basu A, Dar L, Vipat V, Giri S, Potdar V, Choudhary ML, Praharaj I, Jain A, 632 633 Malhotra B, Gawande P, Kalele K, Gupta N, Cherian SS, Abraham P. 2020. First isolation of SARS-CoV-2 from clinical samples in India. Indian J Med Res 151:244-250. 634 Chu H, Chan JF, Yuen TT, Shuai H, Yuan S, Wang Y, Hu B, Yip CC, Tsang JO, Huang 35. 635 X, Chai Y, Yang D, Hou Y, Chik KK, Zhang X, Fung AY, Tsoi HW, Cai JP, Chan WM, 636 Ip JD, Chu AW, Zhou J, Lung DC, Kok KH, To KK, Tsang OT, Chan KH, Yuen KY. 637 2020. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-638 2 and SARS-CoV with implications for clinical manifestations, transmissibility, and 639 laboratory studies of COVID-19: an observational study. Lancet Microbe 1:e14-e23. 640 36. Ren X, Glende J, Al-Falah M, de Vries V, Schwegmann-Wessels C, Qu X, Tan L, 641 Tschernig T, Deng H, Naim HY, Herrler G. 2006. Analysis of ACE2 in polarized epithelial 642 cells: surface expression and function as receptor for severe acute respiratory syndrome-643 644 associated coronavirus. J Gen Virol 87:1691-5.

645 37. Lassi ZS, Moin A, Bhutta ZA. 2016. Zinc supplementation for the prevention of pneumonia
646 in children aged 2 months to 59 months. Cochrane Database Syst Rev 12:CD005978.

647

# 648 SUPPLEMENTARY INFORMATION

649 This article has supplementary information.

650

652 TABLE

# 653 Table – 1 List of mutations in plaque-purified isolates compared to the reference Wuhan

654 strain (MN908947.3).

Virus	Nucleotide	Base	Open reading frame	Amino acid
	position	change		substitution
THSTI-2010-	1227	T→C	ORF1a	M321T
(A, B, C, D)				
	1281	C→T	ORF1a	A339V
	1758	C→T	ORF1a	A498V
	4885	T→C	ORF1a	Synonymous
	6312	С→А	ORF1a	T2016K
	11083	G→T	ORF1a	L3606F
	13730	C→T	ORF1b	A88V
	23929	C→T	Surface glycoprotein (S;	Synonymous
			Spike)	
	28311	C→T	Nucleocapsid	P13L
			phosphoprotein (N)	
THSTI-2010-	27806	G→T	ORF7b	Synonymous
С				

655

# 656 **FIGURE LEGENDS**

# **Figure 1: Kinetics of viral load in VTM and saliva samples of COVID-19 patients.** A-F)

658 SARS-CoV-2 RNA levels were measured by RT-PCR using total RNA isolated from VTM

samples every day after enrolment. G-K) SARS-CoV-2 RNA levels were measured by RT-PCR
using total RNA isolated from saliva and VTM samples every day after enrolment. Data points
indicate geometric mean normalized to RNASe P levels which was used as endogenous controls
for extraction efficiency.

663

Figure 2: Kinetics of secreted inflammatory mediators in COVID-19 patients. A) Daily 664 IFN- $\alpha$ , IFN- $\gamma$  levels (on the left y-axis) were estimated from serum samples of COVID-19 665 patients using luminex assays and copy numbers of viral genome equivalents (on the right-y 666 axis) was estimated from RNA isolated from VTM samples every day. B) The levels of indicated 667 cytokines influencing T-cell functions were estimated from serum samples collected daily from 668 COVID-19 patients. C) The levels of indicated chemokines suggestive of inflammation were 669 estimated from serum samples collected daily from COVID-19 patients. D) The levels of 670 indicated cytokines which are key determinants of inflammatory response were estimated from 671 serum samples collected daily from COVID-19 patients. Columns indicate the median value with 672 95% CI. 673

674

Figure 3: THSTI-BL-2010 plaque-purified isolates. A) Single plaque morphology of THSTIBL-2010 at 72 h pi. Virus from four single plaques were propagated on VeroE6 monolayer
separately. Cytopathic effect was evident at 72 h post-infection for all the four isolates. Images
were captured at 20X magnification. B) VeroE6 cells were used for performing plaque assays
with either the reference SARS-CoV-2 strain or THSTI-BL-2010D.Cells were fixed at 60 h pi
and stained with crystal violet.

Figure 4: Infection of human cell lines. A) Vero E6, Calu-3 and Caco-2 cells were either
mock-infected or infected with THSTI-2010-D at indicated MOI for 24 h. Cells were fixed in
and stained with anti-spike protein antibody and probed with secondary antibody conjugated
with Alexa Fluor 488. Images were captured using Olympus DP80 microscope. Scale bar is 100
µm. B) Growth curve of SARS-CoV-2 Wuhan and THSTI-BL2010D strain were compared on
Vero E6 cells. Vero E6 cells were infected at 0.1 MOI either with Wuhan strain or THSTI
BL2010D. Viral titers were measured at 24 h, 48 h and 72 h in culture supernatants (n=3).

Figure 5. Maximum likelihood phylogeny for SARS CoV2 sequences (n=100). Indian isolates
reported here falls under 19A clade. The sequence of plaque purified isolates are highlighted
with symbol 'star'. The GISAID clades are indicated as mentioned in the inset. The scale bar
indicates the branch lengths measured in number of nucleotide substitution rate per site.

694

695 Figure 6: SARS-CoV-2 infection disrupts epithelial barrier integrity. A) Calu-3 cells grown on transwells at air-liquid interface as described in methods section. Polarized Calu-3 cells were 696 697 infected with SARS-CoV-2 THSTI-BL-2010D at 0.3 MOI. TEER was measured at 24 h pi. 698 TEER values were represented as ohm/cm<sup>2</sup>. B) Viral titres were determined at 24 h pi and represented as pfu/ml. C) Cells were fixed and stained with ZO-1 and Claudin-3 antibodies 699 700 against cellular junctions and spike antibody against viral protein. Nuclei were stained with 701 DAPI. Images were captured at 100X. Representative images of mock and SARS-CoV-2 702 infected cells are displayed. Scale bar is 10 µm. D) Calu-3 cells were treated with indicated concentrations of ZnSO<sub>4</sub> for 24 h and cell viability was measured using CellTiter-Glo® Assay 703 704 kit. E) Calu-3 cells were infected with SARS-CoV-2-THSTI-BL-2010D at 0.3 MOI. After viral

adsorption, cells were treated with 25 and 50  $\mu$ M of ZnSO<sub>4</sub> or as mock treated control. Viral titres were determined as represented as pfu/ml. (n=3). Error bars represent mean  $\pm$  SD. \*p < 0.05, \*\*p < 0.01.

708

709

# 710 SUPPLEMENTARY FIGURE LEGENDS

711 Figure S1: SARS-CoV-2 Indian isolates. Vero E6 cells were infected with nasopharyngeal

swab samples for 1 h and cultured in growth medium thereafter. CPE was evident at 48 h post-

infection. Images were captured using Nikon Eclipse Ti-S microscope at 20X magnification.

714

715 Figure S2: Zinc uptake in Calu-3 cells. Calu-3 cells after incubation with indicated

concentrations of zinc sulfate for 4 h and labile zinc levels were measured by staining with

717 ZinPyr-1 and flow cytometry. The relative change in the mean fluorescence intensities of ZP-1 is

shown in the graph. Error bars represent Mean with SD.

719

720

Figure 1





# Figure 3

THSTI-BL2010 - A THSTI-BL2010 - B



Α

USA-WA1/2020





















**ZnSO<sub>4</sub> (μΜ)**